Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae announces fourth quarter and 2014 year-end financial results and highlights and provides 2015 outlook

Invitae announces fourth quarter and 2014 year-end financial results and highlights and provides 2015 outlook

March 10, 2015

-- Company demonstrates early progress towards achieving its goal of making genetic information more affordable and accessible --

SAN FRANCISCO, March 10, 2015 -- Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the fourth quarter and year ended December 31, 2014. Highlights for the quarter and year include:

  • Delivered more than 1,800 billable reports in the fourth quarter and more than 3,600 billable reports during 2014.
  • Improved cost of goods sold (COGS) by driving the average cost per ...

Read more


Invitae to announce fourth quarter and year-end 2014 financial results and host conference call on March 10, 2015

Invitae to announce fourth quarter and year-end 2014 financial results and host conference call on March 10, 2015

February 24, 2015

SAN FRANCISCO, February 24, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its fourth quarter and year-end 2014 financial results on Tuesday, March 10, 2015. Invitae’s management team will host a conference call on Tuesday, March 10, 2015 at 4:45 p.m. ET/1:45 p.m. PT to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international ...

Read more


Invitae announces completion of initial public offering and full exercise of underwriters’ option to purchase additional shares

Invitae announces completion of initial public offering and full exercise of underwriters’ option to purchase additional shares

February 18, 2015

SAN FRANCISCO, February 18, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the closing of its initial public offering of 7,302,500 shares of common stock at an initial public offering price of $16.00 per share, which included 952,500 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock. Total gross proceeds from the offering were approximately $116.8 million, before deducting ...

Read more


 Invitae announces pricing of initial public offering of common stock

Invitae announces pricing of initial public offering of common stock

February 11, 2015

SAN FRANCISCO, February 11, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the pricing of its initial public offering of 6,350,000 shares of its common stock at an initial offering price of $16.00 per share, for total gross proceeds of $101.6 million before deducting underwriting discounts and commissions and other offering expenses.  The shares of Invitae’s common stock are expected to begin trading on the New York Stock Exchange under the ...

Read more


Invitae announces settlement in lawsuit with Myriad Genetics

Invitae announces settlement in lawsuit with Myriad Genetics

January 26, 2015

SAN FRANCISCOJanuary 26, 2015—Invitae Corporation, a genetic information company, announced today that it had reached a settlement with Myriad Genetics, Inc., the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche, Inc. in their patent dispute concerning Invitae’s genetic testing for the BRCA1, BRCA2 and MUTYH genes (MDL Case No. 2:14-CV-02510; Civil Case No. 2:14-cv-00153-RJS (D. Utah).)

The parties agreed to dismiss with prejudice ...

Read more


Invitae Corporation files registration statement for proposed initial public offering

Invitae Corporation files registration statement for proposed initial public offering

January 09, 2015

SAN FRANCISCO January 9, 2015—Invitae Corporation announced today that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA ...

Read more


Invitae and collaborators present data at San Antonio Breast Cancer Symposium demonstrating use of multi-gene panels for reliable risk assessment in hereditary breast/ovarian cancer patients

Invitae and collaborators present data at San Antonio Breast Cancer Symposium demonstrating use of multi-gene panels for reliable risk assessment in hereditary breast/ovarian cancer patients

December 10, 2014

Invitae’s platform demonstrates high concordance with traditional diagnostic tests for BRCA1 and BRCA2 and increased yield of clinical findings in hereditary cancer risk assessment.

SAN ANTONIO – December 10, 2014 – Invitae Corporation, a genetic information company, announced the presentation of two scientific studies at the 37th Annual San Antonio Breast Cancer Symposium: “Clinical Evaluation of Multi-gene Testing for Hereditary Breast and Ovarian Cancer” (Poster P4-12-04) and “Technical Evaluation of Multi-gene Testing for Heredity Breast and Ovarian Cancer” (Poster P4-12-07).  

The ...

Read more


Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider

Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider

December 03, 2014

SAN FRANCISCO, December 3, 2014 – Invitae Corporation, a genetic information company, announced that its testing services are eligible for coverage by two additional payors, Blue Shield of California and the Centers for Medicare and Medicaid Services (CMS). 

“Securing reimbursement is an important step towards realizing our mission to make genetic testing affordable and accessible for patients,” said Lisa Alderson, chief commercial officer of Invitae.  “Since launching just over a year ago, we have grown our volume rapidly ...

Read more


Invitae receives accreditation for its laboratory from the College of American Pathologists

Invitae receives accreditation for its laboratory from the College of American Pathologists

December 02, 2014

SAN FRANCISCO, December 2, 2014 – Invitae Corporation, a genetic information company, announced that it has received accreditation from the College of American Pathologists (CAP). 

The CAP accreditation is awarded to facilities that meet the highest standards of quality in laboratory services. According to the Commission on Laboratory Accreditation, the U.S. government recognizes the CAP Laboratory Accreditation Program, which began in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. 

During the CAP ...

Read more


Invitae completes $120 million series F financing

Invitae completes $120 million series F financing

October 13, 2014

SAN FRANCISCO, October 13, 2014 – Invitae Corporation, a genetic information company, today announced the completion of a $120 million Series F financing. Invitae plans to use the proceeds to accelerate the build out of its infrastructure for its genetic information business, as well as to expand its global presence. 

New investors participating in the round included (in alphabetical order) The Broe Group, Decheng Capital, Deerfield Management LLC, OrbiMed, Perceptive Advisors, Rock Springs Capital and Wellington Management Company, LLP ...

Read more